AKT1 and breast carcinoma: In conclusion, the ruthenium-fluvastatin complex is accountable for p53 interfering apoptosis in breast carcinoma, facilitated by the intrinsic apoptotic path provoked by Bcl2 and Bax and simultaneously regulating the PI3K/Akt/mTOR pathway in conjunction with MMP9-regulated invasive tumor pathways (Figure 15).